RxDoctor Payments Data

Dang Nguyen, PA

Physician Assistant · Garden Grove, CANPI 1932470788

Payments from drug & device makers

$8,810in general payments, 2019–2025

Across 318 payments — averaging $27.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Gilead$936
  • Novo Nordisk$824
  • Lilly USA, LLC$536
  • Boehringer Ingelheim$499
  • Nestle Healthcare Nutrition Inc.$494
  • plus $4K from 35 others

What the payments were for

  • Travel & lodging$40%
  • Food & beverage$8,806100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,810 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$84,759
Medicare patients
309
Services billed
860

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin105$97,902
FarxigaDapagliflozin Propanediol91$88,155
JanuviaSitagliptin Phosphate76$71,817
RybelsusSemaglutide41$57,629
ProliaDenosumab29$47,693
TrulicityDulaglutide46$47,372
GemtesaVibegron55$47,018
LinzessLinaclotide60$46,845
ZenpepLipase/Protease/Amylase29$39,114
TradjentaLinagliptin36$30,367
VemlidyTenofovir Alafenamide21$29,726
KerendiaFinerenone33$27,477
MyrbetriqMirabegron34$27,169
VascepaIcosapent Ethyl76$21,049
EliquisApixaban28$20,876

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$499$128,270141 claims
AstraZenecaFarxiga, Brilinta$459$101,605103 claims
MerckJanuvia, Janumet$325$85,38193 claims
AbbVieLinzess, Restasis, Namzaric, Creon$470$82,438107 claims
Novo NordiskRybelsus, Ozempic$824$69,66755 claims
AmgenProlia$1,089$47,69329 claims
Lilly USA, LLCTrulicity$536$47,37246 claims
Sumitomo Pharma America, Inc.Gemtesa$22$47,01855 claims
Aimmune Therapeutics, Inc.Zenpep$216$39,11429 claims
GileadVemlidy$936$29,72621 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$331$28,00269 claims
BayerKerendia$468$27,47733 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Garden Grove

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →